GLP-1 combination therapy may unlock new benefits for psoriasis patients
NewsNation reports on new Eli Lilly data in adults with moderate-to-severe psoriasis and obesity. By Week 36, those given Taltz (ixekizumab) plus Zepbound (tirzepatide) showed broader changes in psoriasis-related, immune and metabolic blood biomarkers than those on Taltz alone: 482 proteins and 467 genes versus 140 proteins and 16 genes. The findings are company-reported biomarker measurements, which researchers say only may point to linked immune and metabolic biology.
Why it matters: Relevant to Maryland adults living with both moderate-to-severe psoriasis and obesity, and to the dermatology and obesity-medicine clinicians who refer them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to yahoo.com. October 12, 2026.
